New Recommendations from NBDF’s Medical and Scientific Advisory Council (MASAC)

The three new recommendations concern off-label use for emicizumab for acquired hemophilia A; the use of anti-tissue factor pathway Inhibitors in hemophilia; and the role of social workers in the HTC.

Source: National Bleeding Disorders Foundation, NBDF Notes, November 2025